NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Qi Li also reported that IL-21(50 ng/mL) could increase the number of CD56+CD3+ NK cells among PBMCs (173) revealing the feasibility of IL-15 or 21-secreting CAR-NK in treating CML.